SLZ0 Stock Chart & Stats
€4.67
€0.00(0.00%)
At close: 4:00 PM EDT
€4.67
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.67 - €4.79
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.73M
Enterprise Value-€2.79
Total Cash (Recent Filing)€8.30M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.84
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.46
Shares Outstanding4,475,884
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-272.82
Revenue Forecast (FY)€8.66M
Bulls Say, Bears Say
Bulls Say
Minimal LeverageAn effectively debt-free balance sheet limits interest obligations and reduces repayment pressure while the company advances its pipeline. This gives management greater flexibility to direct available capital toward research and development rather than servicing lenders, although it does not eliminate funding needs.
Improved Equity BaseThe increase in equity provides a stronger capitalization base than in 2025 and may improve resilience during continued clinical development. A larger equity cushion can support operating continuity, though its durability depends on future losses, financing activity, and progress toward revenue generation.
Reduced Historical LossesLower losses and improved burn compared with earlier periods suggest some expense discipline as the company develops its therapeutic candidates. If sustained, this could extend financial runway and make capital use more efficient, even though the business remains pre-revenue and loss-making.
Bears Say
No Commercial RevenueThe absence of revenue means Enveric has not yet demonstrated commercial demand or an internally funded operating model. Continued reliance on preclinical and clinical development leaves the company dependent on future milestones, partnerships, or financing before it can establish recurring revenue.
Persistent Cash BurnSustained operating and free cash outflows consume resources while the company has no revenue base to replenish them. Re-accelerating burn increases dependence on external funding and can restrict the pace of pipeline investment or create dilution pressure before a major partnership or revenue milestone.
Deep Ongoing LossesLarge net losses combined with negative gross profit show that the current operating structure does not yet generate positive economics. This keeps profitability far from breakeven and requires continued funding for research and development, increasing execution pressure over the next several quarters.
Enveric Biosciences News
SLZ0 FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was €4.67 and its highest was €4.79 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is €5.73M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Nov 12, 2026 which is in 42 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on Aug 14, 2026. The company reported -€0.67 earnings per share for the quarter.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 4,475,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -€0.67 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in DE:SLZ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.